Michael Kranda, MBA – Chief Executive Officer, President and Director – Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development. Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).
Sam L. Teichman, MD, FACC, FESC, FACP – Chief Medical Officer and Senior VP of R&D and Director. Dr. Teichman has nearly 30 years of global clinical research and drug development leadership experience across broad therapeutic areas with a focus on cardiovascular disease and heart failure. As Senior Vice President of R&D and CMO at Corthera, he led the medical effort to develop serelaxin for the treatment of acute heart failure. Corthera was acquired by Novartis in 2010. More recently, Dr. Teichman was CMO of Chiasma leading the global development program for oral octreotide culminating in a worldwide license agreement with Roche/Genentech in 2013. In addition, he has worked at Genentech, Glycomed and ARYx Therapeutics and has supported programs as a consultant for Scios/J&J, CryoCor, Biomarin, CIRM and Vivus. He has over 80 published original articles, reviews and abstracts in peer-reviewed journals.
BEATBio BOARD OF DIRECTORS
Michael Kranda – Chief Executive Officer and President.
Sam Teichman, MD – Chief Medical Officer and Senior VP of R&D.
Jim Leggett, M.D. (Chairman) – Dr. Leggett is the Medical Director of the Diagnostic Vascular Laboratory at Overlake Internal Medicine Associates, and, Medical Director of the Hope Heart Institute. Dr. Leggett received his MD from the University of Arkansas Medical Sciences Center, and his internal medicine and cardiology training at the University of Washington and University of New Mexico School of Medicine respectively. Dr. Leggett is board certified in internal medicine and cardiovascular medicine, and is an expert in the treatment of cardiovascular disease, and non-invasive and invasive techniques to treat coronary and peripheral artery disease.
Michael Regnier, Ph.D. – Scientific co-founder and Scientific Advisory Board Member. Dr. Regnier is Professor and Vice Chairman of the department of Bioengineering at the University of Washington. Dr. Regnier leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. He is an established Investigator of the American Heart Association, and an Affiliate Investigator of the Benaroya Research Institute. Dr. Regnier holds a Ph.D. in Biology and Neurobiology from the University of Southern California
Craig Tall – Mr. Tall is the managing director of CET Capital Partners LLC, which provides assistance in mergers and acquisitions, financing strategies and other financial matters. Prior to founding CET Capital Partners, he served as Vice Chairman of Washington Mutual Inc. from1999 to 2004 and before that, beginning in 1985, as Executive Vice President of corporate development for Washington Mutual. Earlier in his career he was President and owner of an employee benefits consulting firm. He presently holds board positions for a diverse group of companies, including The Space Needle Corporation, True Blue Inc. (NYSE), Cascadia Capital and Vittana (a not-for-profit global micro student lender). Craig holds a B.S. in Economics from the University of Pennsylvania’s Wharton School.
Chad Waite (Observer for the WFund) – Mr. Waite joined OVP Venture Partners in 1987 and focuses on investments in both the digitalbiology, and network security sectors. His investments include 4thPass, Accelerator, Adapx, Cardima, CellPro, Complete Genomics, Corixa, Filenet, GenoLogics, Limerick BioPharma, NanoString, Quantum Medical, Raytel Medical, Rosetta Inpharmatics, and Seattle Genetics. He currently serves on the Board of Directors of Accelerator, Adapx, Aggregate Knowledge, NanoString (NSTG), Symform, Talyst, The W Fund and Verdezyne. Prior to joining OVP, Chad was a General Partner at Hambrecht & Quist Venture Partners where he focused on investments in IT and life sciences. Chad received his BA in History from Kenyon College and his MBA from Harvard Business School. He is a Trustee at Kenyon College and has also served as a board member of the NVCA.
Charles E. Murry, M.D., Ph.D. – Scientific co-founder and Chairman of the Scientific Advisory Board. Dr. Murry is Professor of Pathology, Bioengineering and Medicine/Cardiology and Director of the Center for Cardiovascular Biology at the University of Washington. Dr. Murry is one of the foremost experts in cardiac repair, cardiac stem cells and tissue regeneration.
Buddy Ratner, Ph.D. – Scientific co-founder and Scientific Advisory Board member. Professor of Bioengineering and Chemical engineering, and, Director of the University of Washington Engineered Biomaterials. Dr. Ratner is a National Academy of Engineering member and is one of the most highly regarded experts in the area of bioengineering and biomaterials.
Michael Laflamme, M.D., Ph.D. – Scientific co-founder and Scientific Advisory Board member. Associate Professor of Pathology, University of Washington Center for Cardiovascular Biology. Dr. Laflamme is a leader in the field of cardiac physiology, stem cell-derived cardiac tissues and cardiac pacemaker cells.
Michael Regnier, Ph.D. -Scientific co-founder and Scientific Advisory Board Member. Dr. Regnier is Professor and Vice Chairman of the department of Bioengineering at the University of Washington. Dr. Regnier leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. He is an established Investigator of the American Heart Association, and an Affiliate Investigator of the Benaroya Research Institute. Dr. Regnier holds a Ph.D. in Biology and Neurobiology from the University of Southern California